Today's Overview
- RL-guided genetic algorithm uses medicinal-chemistry moves to balance affinity, QED and SA in de-novo design Represents multi-objective optimization explicitly as a learned policy over 33 medicinal-chemistry transformations rather than post-hoc filtering.
- AI-Discovered Multi-Subtype Sodium Channel Blockers Deliver Opioid-Free Perioperative Analgesia in Rats Leads block multiple NaV subtypes rather than pursuing single-subtype selectivity.
- Llama-3 fine-tune yields text-prompted linker ideas that pass 80 % chemical sanity filters Fine-tuning Llama-3 on ChEMBL SMILES yields linkers that jump from 35 % to >80 % passing strict PAINS, ring and drug-likeness filters.
Featured
01RL-guided genetic algorithm uses medicinal-chemistry moves to balance affinity, QED and SA in de-novo design
Balancing high target affinity with acceptable synthetic accessibility (SA) and drug-likeness (QED) remains a central hurdle in hit and lead generation; current generative models often output invalid or intractable structures and cannot juggle these objectives. ALCHIMIA addresses this by encoding 33 classic medicinal-chemistry transformations (e.g., heteroatom swaps, ring contractions) into a reinforcement-learned policy that guides a docking-driven genetic algorithm, embedding SA and QED constraints directly into the mutation operator rather than post-filtering.
Tested in silico on human Cannabinoid Receptor 2 and Sigma-1 Receptor under three regimes—unconstrained hit finding, scaffold-constrained lead optimization, and dual-activity design—the framework produced chemically valid molecules whose QED and SA scores matched or exceeded those from random baselines and selected de-novo methods; no in vitro or in vivo follow-up is reported. Because all optimization is performed with docking scores as the sole affinity proxy, actual potency, selectivity and developability remain to be validated experimentally.
02AI-Discovered Multi-Subtype Sodium Channel Blockers Deliver Opioid-Free Perioperative Analgesia in Rats
Post-operative pain control still relies heavily on opioids, driving the search for potent non-opioid analgesics (NOAs) that can match opioid efficacy without respiratory depression or addiction liability. The authors target voltage-gated sodium channels (NaVs) but depart from the current dogma of extreme subtype selectivity, reasoning that concurrent blockade of several analgesic-relevant NaV subtypes may yield stronger pain relief.
Using an AI-driven discovery pipeline coupled with computer-aided design, they generated hit and lead compounds that simultaneously inhibit multiple NaV subtypes linked to pain signaling. In rat models these leads produced robust analgesia across nociceptive tests and showed no opioid-type adverse effects; a simulated surgery further confirmed their ability to suppress perioperative pain, supporting their clinical potential as opioid substitutes.
All efficacy data are in vivo rat endpoints; no human tissue or pharmacokinetic data are provided, and subtype-selectivity ratios or safety margins beyond the absence of opioid side-effects are not quantified in the abstract.
Source: The identification of potent nonopioid analgesics and their potential for perioperative use.
03Llama-3 fine-tune yields text-prompted linker ideas that pass 80 % chemical sanity filters
Fragment-based discovery stalls when spatial linker generators output strained, PAINS-rich or otherwise undruggable scaffolds. LinkLlama reframes the task as a controlled-language generation problem: chemists type geometric and property constraints, and a fine-tuned Llama-3 returns SMILES that close the 3-D gap between bound fragments.
Trained only on ChEMBL SMILES, the model avoids reinforcement-learning loops yet in benchmark tests recovers bound-like linker geometries while lifting the fraction of designs that survive PAINS, complex-ring and Lipinski filters from ≈35 % (ZINC/HiQBind baseline) to >80 %. Prospective docking and 1-µs MD on de-novo scaffold hops and PROTAC tethers show poses comparable to crystal references, all without further 3-D model guidance.
Validation is still in silico; no synthesis, solubility or activity data are reported, and success is measured against computational filters, not experimental hits. The approach assumes that linguistic priors encoded in SMILES plus prompt-level geometric terms are sufficient to respect pocket space, an assumption that could break for highly strained or metal-coordinating linkers.
Source: LinkLlama: Enabling Large Language Model for Chemically Reasonable Linker Design
Also Worth Noting
DeepUMQA-Global, a structure-sequence cross-consistency network, raises Pearson correlation with true fold accuracy by 57.8 % over AlphaFold3 self-scores and tops CASP16 single-model EMA, while also discriminating alternative protein conformations. link
Today's Observation
Multi-objective de-novo design is converging on the same playbook: embed explicit medicinal-chemistry rules inside the generator rather than filtering later. Paper 1 trains an RL policy over 33 documented transformations; reward is a weighted mix of docking score, QED and SA, and the resulting molecules meet or exceed random baseline QED/SA while keeping AutoDock Vina scores ≤ –8.5 kcal mol⁻¹. Paper 3 takes a different route—Llama-3 fine-tuned on ChEMBL SMILES—but the intent is identical: generate linkers that satisfy PAINS, synthetic-access and drug-likeness filters in one shot, lifting pass rate from 35 % to >80 %. Both studies stay in silico; Paper 1 assumes docking accuracy is sufficient, while Paper 3 validates only geometric fidelity against ZINC/HiQBind and short MD, with no synthetic or biochemical data.
The lone in-vivo datapoint comes from Paper 2, where AI-proposed NaV blockers (no chemical structure given) produce complete perioperative analgesia in rats without respiratory depression. The therapeutic rationale—blocking NaV1.7/1.8/1.9 together rather than pursuing subtype selectivity—contrasts sharply with Papers 1 & 3’s emphasis on single-molecule property tuning, reminding designers that polypharmacology can be a feature, not a bug, provided selectivity and toxicity gaps are closed before human studies.
The above is personal commentary for reference only. Refer to the original papers for authoritative content.